Mpox Vaccines: Challenges Persist as Congo Receives First Batch Of Doses Almost 2 Years After It Declared Epidemic
Mpox Vaccines: Challenges Persist as Congo Receives First Batch Of Doses Almost 2 Years After It Declared Epidemic
On Thursday, the European Commission said around 100,000 mpox vaccine doses arrived in the Democratic Republic of Congo (DRC), making these the first delivery of the vaccine to the country.
歐盟委員會週四表示，約10萬mpox疫苗已抵達剛果民主共和國（DRC），這是該疫苗首次運送到該國。
A second delivery amounting to around 100,000 vaccines is expected to arrive in the coming days.
第二批總額約爲100,000支疫苗的交付預計將在未來幾天內到達。
These vaccines are part of the 215,000 MVA-BN vaccine doses that the European Commission's Health Emergency Preparedness and Response Authority procured and pledged to share with affected African countries as an immediate response to the mpox outbreak.
這些疫苗是歐盟委員會衛生應急準備和反應局採購並承諾與受影響的非洲國家共享的21.5萬劑MVA-BN疫苗的一部分，以立即應對mpox疫情。
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic A/S (OTC:BVNRY) (OTC:BVNKF) is a non-replicating smallpox vaccine and the only mpox vaccine approved in the EU/EEA and the U.K. (marketed as Imvanex), the U.S. and Switzerland (marketed as Jynneos), and in Canada (marketed as Imvamune).
MVA-BN 或改性疫苗 Ankara-Bavarian Nordic A/S（場外交易代碼：BVNRY）（場外交易代碼：BVNKF）是一種非複製性天花疫苗，也是歐盟/歐洲經濟區和英國（作爲 Imvanex 銷售）、美國和瑞士（以 Jynneos 的名義銷售）以及加拿大（作爲 Imvneos 銷售）批准的唯一多痘疫苗阿穆恩）。
An additional 351,500 doses from France, Germany, Spain, Malta, Portugal, Luxembourg, Croatia, Austria, Poland, and potentially some other Member States will be donated to the Africa CDC to distribute to affected countries.
來自法國、德國、西班牙、馬耳他、葡萄牙、盧森堡、克羅地亞、奧地利、波蘭以及可能還有其他一些會員國的另外351,500劑將捐贈給非洲疾病預防控制中心，分發給受影響國家。
This brings the total vaccine doses donated from Team Europe to at least 566,500.
這使歐洲隊捐贈的疫苗總劑量達到至少566,500劑量。
Congo received the doses on Thursday, more than 18 months after the country declared the situation an epidemic.
剛果在週四收到了疫苗，也就是該國宣佈疫情已過去18個多月。
Assigning blame for the sluggish distribution of mpox vaccines in Congo proves challenging due to a multitude of factors, the NPR report notes.
美國國家公共電臺的報告指出，由於多種因素，將mpox疫苗分發緩慢歸咎於剛果具有挑戰性。
As of June 27, Congo's regulatory body had not approved mpox vaccines for use. Subsequent donations from the U.S. have been stalled as the Congolese government finalizes pre-shipment requirements, such as proper vaccine storage and handling.
截至6月27日，剛果監管機構尚未批准使用mpox疫苗。隨着剛果政府最終確定疫苗的正確儲存和處理等裝運前要求，美國的後續捐款一直處於停滯狀態。
Many low- and middle-income countries rely on the World Health Organization (WHO) to evaluate vaccine safety and efficacy. Yet, the WHO has not approved any mpox vaccines, still relatively new, despite their authorization by U.S. and European health authorities during the global mpox outbreak in 2022.
許多低收入和中等收入國家依賴世界衛生組織（WHO）來評估疫苗的安全性和有效性。然而，儘管在2022年全球mpox疫情期間獲得了美國和歐洲衛生當局的批准，但世衛組織尚未批准任何mpox疫苗，這些疫苗仍然相對較新。
There remain significant unknowns about the vaccines, especially regarding their effectiveness against the virus strain currently spreading in Congo, which has evolved into a new variant.
疫苗仍有大量未知數，特別是其對抗目前在剛果傳播的病毒株的有效性，該病毒株已演變爲一種新的變種。
The African response to the mpox crisis mirrors past challenges faced during the COVID pandemic when vaccine access was severely limited for lower-income nations.
非洲對mpox危機的反應反映了過去在COVID大流行期間面臨的挑戰，當時低收入國家的疫苗供應受到嚴重限制。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：此內容部分是在人工智能工具的幫助下製作的，並由Benzinga的編輯審閱和發佈。
- What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
- 週五以細價股血癌爲重點的生物製藥公司怎麼了？
Photo by NIAID via Flickr
照片由 NIAID 通過 Flickr 拍攝
譯文內容由第三人軟體翻譯。